Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data.
Di Filippo Y, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Beylot-Barry M, Stoebner PE, Dupuy A, Stephan A, Grob JJ, Lefevre W, Oriano B, Allayous C, Lebbé C, Montaudié H. Di Filippo Y, et al. Among authors: lefevre w. Ann Oncol. 2021 Apr;32(4):542-551. doi: 10.1016/j.annonc.2020.12.012. Epub 2020 Dec 30. Ann Oncol. 2021. PMID: 33385520 Free article.
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.
Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudié H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le-Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C. Carlet C, et al. Among authors: lefevre w. J Am Acad Dermatol. 2022 Feb;86(2):345-352. doi: 10.1016/j.jaad.2021.06.849. Epub 2021 Jun 18. J Am Acad Dermatol. 2022. PMID: 34153388
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Girod M, Dalle S, Mortier L, Dalac S, Leccia MT, Dutriaux C, Montaudié H, de Quatrebarbes J, Lesimple T, Brunet-Possenti F, Saiag P, Maubec E, Legoupil D, Stoebner PE, Arnault JP, Lefevre W, Lebbe C, Dereure O. Girod M, et al. Among authors: lefevre w. JCO Precis Oncol. 2022 Nov;6:e2200075. doi: 10.1200/PO.22.00075. JCO Precis Oncol. 2022. PMID: 36356284
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).
Russo D, Dalle S, Dereure O, Mortier L, Dalac-Rat S, Dutriaux C, Leccia MT, Legoupil D, Montaudié H, Maubec E, De Quatrebarbes J, Arnault JP, Brocard FG, Saïag P, Dreno B, Allayous C, Oriano B, Lefevre W, Lebbé C, Boussemart L. Russo D, et al. Among authors: lefevre w. Front Oncol. 2023 Oct 23;13:1250026. doi: 10.3389/fonc.2023.1250026. eCollection 2023. Front Oncol. 2023. PMID: 37936607 Free PMC article.
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C. Macaire C, et al. Among authors: lefevre w. Melanoma Res. 2024 Nov 11. doi: 10.1097/CMR.0000000000000973. Online ahead of print. Melanoma Res. 2024. PMID: 39527777
16 results